150 related articles for article (PubMed ID: 32953522)
1. A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer.
Jin S; Zhou C; Hou X; Fan Z; Zhao J; Ai X; Chu Y; Chen R; Guo R; Chen L
Transl Lung Cancer Res; 2020 Aug; 9(4):1507-1515. PubMed ID: 32953522
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J
Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers.
Wu H; Ji H; Yang W; Zhang M; Guo Y; Li B; Wang J; Chen R; Chen Y; Wang X
BMC Cancer; 2022 Sep; 22(1):1020. PubMed ID: 36167530
[TBL] [Abstract][Full Text] [Related]
4. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
Yu Y; Qian J; Shen L; Ji W; Lu S
Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer.
He J; Hu X; Chen L; Liu Q; Jiang Y
Front Genet; 2022; 13():850290. PubMed ID: 35646096
[No Abstract] [Full Text] [Related]
6. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
[TBL] [Abstract][Full Text] [Related]
7. Pleural effusion supernatant: a reliable resource for cell-free DNA in molecular testing of lung cancer.
Thakur S; Rathor A; Jain S; Nambirajan A; Khurana S; Malik PS; Jain D
J Am Soc Cytopathol; 2024 Mar; ():. PubMed ID: 38704351
[TBL] [Abstract][Full Text] [Related]
8. [The study of pleural effusion supernatant cell-free tumor DNA in tumor mutational burden assessment of advanced lung cancer].
Tong L; Ding N; Li JM; Xu XB; Zhang Y; Ye MS; Li C; Zhang X; Hong QY; Zhou J; Bai CX; Hu J
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Aug; 42(8):596-601. PubMed ID: 31378021
[No Abstract] [Full Text] [Related]
9. Genomic Alterations Identification and Resistance Mechanisms Exploration of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study.
Shen F; Liang N; Fan Z; Zhao M; Kang J; Wang X; Hu Q; Mu Y; Wang K; Yuan M; Chen R; Guo W; Dong G; Zhao J; Bai J
Front Oncol; 2022; 12():889591. PubMed ID: 35814426
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma.
Song Z; Cai Z; Yan J; Shao YW; Zhang Y
Transl Lung Cancer Res; 2019 Aug; 8(4):392-400. PubMed ID: 31555514
[TBL] [Abstract][Full Text] [Related]
11. Sensitive cell-free tumor DNA analysis in supernatant pleural effusions supports therapy selection and disease monitoring of lung cancer patients.
de Kock R; Knoops C; Baselmans M; Borne BVD; Brunsveld L; Scharnhorst V; Deiman B
Cancer Treat Res Commun; 2021; 29():100449. PubMed ID: 34481168
[TBL] [Abstract][Full Text] [Related]
12. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N
Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807
[TBL] [Abstract][Full Text] [Related]
13. Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens.
Liu L; Shao D; Deng Q; Tang H; Wang J; Liu J; Guo F; Lin Y; Peng Z; Mao M; Kristiansen K; Ye M; He J
J Thorac Dis; 2018 May; 10(5):2631-2637. PubMed ID: 29997924
[TBL] [Abstract][Full Text] [Related]
14. Molecular Profiling for Supernatants and Matched Cell Pellets of Pleural Effusions in Non-Small-Cell Lung Cancer.
Xiang C; Huo M; Ma S; Guo L; Zhao R; Teng H; Zhang J; Han Y
J Mol Diagn; 2020 Apr; 22(4):513-522. PubMed ID: 32036088
[TBL] [Abstract][Full Text] [Related]
15. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
16. Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling.
Guo Z; Xie Z; Shi H; Du W; Peng L; Han W; Duan F; Zhang X; Chen M; Duan J; Lin J; Chen X; Lizaso AA; Han-Zhang H; He J; Yin W
Thorac Cancer; 2019 Apr; 10(4):823-831. PubMed ID: 30779318
[TBL] [Abstract][Full Text] [Related]
17. Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer.
Choudhury Y; Tan MH; Shi JL; Tee A; Ngeow KC; Poh J; Goh RR; Mong J
Front Med (Lausanne); 2022; 9():758464. PubMed ID: 35223889
[TBL] [Abstract][Full Text] [Related]
18. A Combined test using both cell sediment and supernatant cell-free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients.
Kawahara A; Fukumitsu C; Azuma K; Taira T; Abe H; Takase Y; Murata K; Sadashima E; Hattori S; Naito Y; Akiba J
Cytopathology; 2018 Apr; 29(2):150-155. PubMed ID: 29363841
[TBL] [Abstract][Full Text] [Related]
19. Performance of different methods for detecting T790M mutation in the plasma of patients with advanced NSCLC after developing resistance to first-generation EGFR-TKIs in a real-world clinical setting.
Hou T; Zeng J; Xu H; Su S; Ye J; Li Y
Mol Clin Oncol; 2022 Apr; 16(4):88. PubMed ID: 35251639
[TBL] [Abstract][Full Text] [Related]
20. Analysis of EGFR mutation status in malignant pleural effusion and plasma from patients with advanced lung adenocarcinoma.
Son SM; Woo CG; Han HS; Lee KH; Lim YH; Lee OJ
Clin Chem Lab Med; 2020 Aug; 58(9):1547-1555. PubMed ID: 32229655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
